News

Christopher McGhee says that, along with the acquisition, Current Health will have a "return to scrappiness and that startup spirit."

The company offers an AI-enabled workflow automation platform for administrative tasks pertaining to specialty medications. 

The company will use the funds to hasten product development, engineering and go-to-market efforts to meet market demand.  

Connor Glass, founder and CEO of Phantom Neuro, discusses the company's muscle-machine interface that allows individuals with limb loss to control robotic limbs and systems using electrical activity from their own muscles.

The company will use the funds to invest in research and development and to scale its voice AI platform.   

Employees will have access to clinical content and more than 900 U.S. clinics that specialize in fertility, urology and menopause.  

The company will use the funds to advance its AI-enabled robotic platform for cataract and other eye surgeries, with plans to begin human clinical trials this year.

The Series E funding comes four months after the company secured $250 million in a Series D round.

Selected early versions will be slated for real-world deployment. 

The partnership has been terminated less than two months after launch as Novo Nordisk alleges Hims & Hers is illegally selling copycat drugs and using deceptive marketing practices.